Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.47 |
| ▸ | JMJD6 | Q6NYC1 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2671291 | 0.89 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1RAB9ANPC1CYP1A2 | |
| SCHEMBL6982791 | 0.83 | LMNA (0.50) | ALDH1A1L3MBTL1RAB9ANPC1CYP1A2 | |
| Hydrochloric Acid SCHEMBL6974947 | 0.82 | LMNA (0.49) | ALDH1A1L3MBTL1RAB9ANPC1CYP1A2 | |
| SCHEMBL2671186 | 0.81 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1RAB9ANPC1CYP1A2 | |
| SCHEMBL5766348 | 0.78 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1RAB9ANPC1CYP1A2 | |
| SCHEMBL1680503 | 0.78 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1RAB9ANPC1CYP1A2 | |
| SCHEMBL6437644 | 0.78 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1RAB9ANPC1CYP1A2 | |
| SCHEMBL30527962 | 0.77 | PLAU (0.59) | ALDH1A1KDM4EMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL2671321 | 0.77 | HIPK2 (0.49) | L3MBTL1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL2671644 | 0.77 | PLAU (0.59) | ALDH1A1KDM4EMAPTSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2952514-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | Pfizer Inc (US) | 2015-12-09 | — | — | EP | disclosed |
| US-9181252-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181252-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181252-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150152109-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152109-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152109-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-06-04 | — | — | US | disclosed |
| EP-2632925-B1 | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER (US) | 2015-05-27 | — | — | EP | disclosed |
| EP-2632925-B1 | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER (US) | 2015-05-27 | — | — | EP | disclosed |
| US-8993586-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150025098-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-8859773-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859773-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859773-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2632925-A1 | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS | Pfizer Inc (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC | 2012-05-03 | — | — | US | disclosed |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC | 2012-05-03 | — | — | US | disclosed |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC | 2012-05-03 | — | — | US | disclosed |
| WO-2012056372-A1 | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012056372-A1 | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025098-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | ALDH1A1 158/4885L3MBTL1 1219/4885RAB9A 2413/4885 |
| US-20150152109-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | ALDH1A1 158/4885L3MBTL1 1219/4885RAB9A 2413/4885 |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | ALDH1A1 158/4885L3MBTL1 1219/4885RAB9A 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.